134 related articles for article (PubMed ID: 2719737)
1. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
Werner RG; Langlouis-Gau H
Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
[TBL] [Abstract][Full Text] [Related]
2. Validation of biotechnological production processes.
Werner RG; Langlouis-Gau H; Walz F; Allgaier H; Hoffmann H
Arzneimittelforschung; 1988 Jun; 38(6):855-62. PubMed ID: 3052464
[TBL] [Abstract][Full Text] [Related]
3. Successful development of recombinant DNA-derived pharmaceuticals.
Werner RG; Pommer CH
Arzneimittelforschung; 1990 Nov; 40(11):1274-83. PubMed ID: 2085342
[TBL] [Abstract][Full Text] [Related]
4. Consistency and stability of recombinant fermentations.
Wiebe ME; Builder SE
Dev Biol Stand; 1994; 83():45-54. PubMed ID: 7883099
[TBL] [Abstract][Full Text] [Related]
5. Genetic stability of rDNA production systems, a case report.
Chiu YY
Dev Biol Stand; 1994; 83():93-7. PubMed ID: 7883104
[TBL] [Abstract][Full Text] [Related]
6. Presentation of the EEC directive (81/852)--quality.
Lee AM
Dev Biol Stand; 1992; 79():39-41. PubMed ID: 1286763
[TBL] [Abstract][Full Text] [Related]
7. Control of therapeutic goods produced by recombinant DNA technology.
Breschkin A
Dev Biol Stand; 1987; 67():207-11. PubMed ID: 3475226
[TBL] [Abstract][Full Text] [Related]
8. Quality assurance of products manufactured by recombinant DNA technology. Introduction and elements of a philosophy.
van Noordwijk J
Arzneimittelforschung; 1988 Jul; 38(7):943-7. PubMed ID: 3207439
[TBL] [Abstract][Full Text] [Related]
9. Development of fermentation process for rDNA products.
Cossar D
Curr Opin Drug Discov Devel; 2001 Nov; 4(6):756-9. PubMed ID: 11899615
[TBL] [Abstract][Full Text] [Related]
10. Industry perspective on the validation of column-based separation processes for the purification of proteins. Parenteral Drug Association.
J Parenter Sci Technol; 1992; 46(3):87-97. PubMed ID: 1522447
[TBL] [Abstract][Full Text] [Related]
11. Appropriate mammalian expression systems for biopharmaceuticals.
Werner RG; Noé W; Kopp K; Schlüter M
Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
[TBL] [Abstract][Full Text] [Related]
12. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
Jones AJ; O'Connor JV
Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
[TBL] [Abstract][Full Text] [Related]
13. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality.
Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A
J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762
[TBL] [Abstract][Full Text] [Related]
14. FDA perspective on specifications for biotechnology products--from IND to PLA.
Murano G
Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
[TBL] [Abstract][Full Text] [Related]
15. Effects of fermentation on product consistency.
Lubiniecki AS; Anumula K; Callaway J; L'Italien J; Oka M; Okita B; Wasserman G; Zabriskie D; Arathoon R; Builder S
Dev Biol Stand; 1992; 76():105-15. PubMed ID: 1478331
[TBL] [Abstract][Full Text] [Related]
16. Mammalian cell cultures. Part II: Genetic engineering, protein glycosylation, fermentation and process control.
Werner RG; Noé W
Arzneimittelforschung; 1993 Nov; 43(11):1242-9. PubMed ID: 8292072
[TBL] [Abstract][Full Text] [Related]
17. [High-cell density cultivation of recombinant Escherichia coli for production of TRAIL by using a 2-stage feeding strategy].
Zhang Y; Shen YL; Xia XX; Sun AY; Wei DZ; Zhou JS; Zhang GJ; Wang LH; Jiao BH
Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):408-13. PubMed ID: 15971615
[TBL] [Abstract][Full Text] [Related]
18. WHO Expert Committee on specifications for pharmaceutical preparations.
World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
[TBL] [Abstract][Full Text] [Related]
19. Genetic and phenotypic markers and their relationship to product quality and consistency.
Adamson SR; Charlebois TS
Dev Biol Stand; 1994; 83():31-44. PubMed ID: 7883098
[TBL] [Abstract][Full Text] [Related]
20. Identification of tobramycin impurities for quality control process monitoring using high-performance anion-exchange chromatography with integrated pulsed amperometric detection.
Hanko VP; Rohrer JS; Liu HH; Zheng C; Zhang S; Liu X; Tang X
J Pharm Biomed Anal; 2008 Aug; 47(4-5):828-33. PubMed ID: 18486398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
